Form 4 for PHAT Phathom Pharmaceuticals, Inc.
Accepted 2023-11-03 00:00:00 ET · period of report 2023-11-01 · accession 0001209191-23-054346 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-11-03 | 2023-11-01 | PHAT | Curran Terrie | Pres, Chief Executive, Dir | A - Grant | $0.00 | +37.5K | 427.2K | +10% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-11-01 | A | A | 37,500 | $0.00 | 427,171 | D | — | — | (F1) Represents shares earned with respect to performance stock unit awards granted on July 1, 2020 and January 19, 2023 that contained a performance-vesting requirement that was satisfied on November 1, 2023. |